| Teitur Trophics–Sound Bioventures: investment, 202303 financing round Series A totalling €28m incl co-lead investor Sound Bioventures |
2023-03-14 |
| Teitur Trophics–Sunstone Life Science: investment, 202303 financing round Series A totalling €28m incl co-lead investor Sunstone Life Science Ventures |
2023-03-14 |
| Teitur Trophics–Sweden (govt): investment, 202303 financing round Series A totalling €28m incl new + co-investor Industrifonden |
2023-03-14 |
| Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings |
2020-03-13 |
| Tempus Labs–Novo Group: investment, 202012 financing round Series G-2 totalling $200m incl existing investor Novo Holdings |
2020-12-10 |
| Tempus Labs–SEVERAL: credit, 202012 convertible debt financing $250m |
2020-12-10 |
| Tempus Labs–SEVERAL: investment, 202003 financing round Series G $100m incl Baillie Gifford + Franklin Templeton + NEA + Novo Holdings + T Rowe Price |
2020-03-13 |
| Tempus Labs–SEVERAL: investment, 202012 financing round Series G-2 $200m incl Baillie Gifford + Franklin Templeton + Google + Novo + T Rowe Price |
2020-12-10 |
| TenAces Biosciences–Aion Labs: investment, 202401 founding investor Aion Labs announces TenAces |
2024-01-30 |
| Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc |
2021-02-24 |
| The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings |
2020-11-03 |
| Themis Bioscience–Hadean Ventures: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Hadean Ventures |
2019-09-18 |
| Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures |
2019-09-18 |
| Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
| Thermo Fisher–Bico: MS-based single cell proteomics, 202111– co-marketing Cellenion’s cellenONE + proteoCHIP with Orbitrap MS systems + TMT technology |
2021-11-15 |
| Thermo Fisher–Symphogen: mass spectrometry, 201810– collab developm biopharma QC workflows using Q Exactive Plus Orbitrap LC-MS/MS system |
2018-10-29 |
| Traceless Materials–SEVERAL: investment, 202309 financing round Series A €36.6m led by UB FIGG plus other new + all existing investors |
2023-09-25 |
| Traceless Materials–United Bankers: investment, 202309 financing round Series A totalling €36.6m incl new + lead investor UB FIGG |
2023-09-25 |
| Trek Therapeutics–Medivir: virostatic agent, 201608– license excl €na ww excl Greater China for nucleotid poylmerase inhibitor MIV-802 |
2016-08-17 |
| Trevi Therapeutics–Lundbeck: investment, 201707 financing round Series C totalling $50m incl new + co-investor Lundbeckfond Ventures |
2017-07-20 |
| Trevi Therapeutics–SEVERAL: investment, 201707 financing round Series C $50m led by NEA + incl Lundbeckfond et al |
2017-07-20 |
| TTP Group–Battery Ventures: investment, 201810 acquisition €na of TTP Labtech from TTP Group by Battery Ventures |
2018-09-27 |
| Tubulis–EQT: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor EQT Life Sciences |
2024-03-14 |
| Tubulis–SEVERAL: investment, 202403 financing round Series B2 €128m led by EQT Life Sciences + Nextech Invest |
2024-03-14 |
| UbiSim–Labster: investment, 202110– acquisition of UbiSim by Labster SIGNED |
2021-10-14 |
| UBM–Cision: investment, 201512–201606 acquisition $841m with $810m in cash + $31m preferred equity of PR Newswire by Cision from UBM plc |
2015-12-15 |
| Ultimovacs–Immuneed: investment, 201807 acquisition 5.41% shareholding as part of compensation for sale of TET Pharma business to Ultimovacs |
2018-07-01 |
| UmanDiagnostics–Quanterix: investment, 201906–201907 acquisition $16m in cash + $6.5m in common stock |
2019-06-26 |
| Umetrics–MKS Instruments: investment, 2006 acquisition by MKS Instruments |
2006-01-01 |
| uMotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC |
2020-09-03 |
| Unchained Labs–SEVERAL: investment, 201706 financing round Series C $13m incl existing investors Novo Ventures + Canaan Partnes + TPG Biotech |
2017-06-29 |
| Unibio–SEVERAL: investment, 201908 financing round $15m (£12.4m) from existing + new shareholders led by West Hill Capital |
2019-08-28 |
| Unibio–West Hill Capital: investment, 201908 financing round totalling $15m (£12.4m) incl lead investor West Hill Capital |
2019-08-28 |
| United States (govt)–Cobo Technologies: genome editing, 201904– collab Cobo beomes member of NIST Genome Editing Consortium |
2019-04-15 |
| Univ Aarhus–Novo Group: grant, 202109–202808 grant DKK630m (€84.7m) to establish NNF CO2 Research Center at AU + six satellite institutes |
2021-09-22 |
| Univ Copenhagen–Resolve Biosciences: Molecular Cartography technology, 202210 supply to Novo Nordisk Foundation Center existent |
2022-10-24 |
| Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications |
2020-06-08 |
| VarmX–EQT: investment, 202305 financing round Series B2 totalling €30m incl existing + co-investor EQT Life Sciences (formerly LSP) |
2023-05-25 |
| VarmX–EU (govt): investment, 202305 financing round Series B2 totalling €30m incl new + co-investor EIC Fund |
2023-05-25 |
| VarmX–Lundbeck: investment, 202305 financing round Series B2 totalling €30m incl existing + co-investor Lundbeckfonden BioCapital |
2023-05-25 |
| VarmX–SEVERAL: investment, 202007 financing round Series B €32m co-led by Ysios Capital + INKEF Capital |
2020-07-08 |
| VarmX–SEVERAL: investment, 202305 financing round Series B2 €30m led by Sound Bioventures |
2023-05-25 |
| VarmX–Sound Bioventures: investment, 202305 financing round Series B2 totalling €30m incl new + lead investor Sound Bioventures |
2023-05-25 |
| VBM Laboratoriet–Eurofins: investment, 201703 acquisition of VBM by Eurofins |
2017-03-24 |
| VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors |
2020-10-15 |
| VectorY–EQT: investment, 202311 financing round Series A totalling €129m incl new + co-lead investor EQT Life Sciences Dementia Fund |
2023-11-13 |
| VectorY–SEVERAL: investment, 202311 financing round Series A €129m co-led by EQT Life Sciences + Forbion Growth Opportunities Fund |
2023-11-13 |
| Veloxis Pharmaceuticals–Asahi Kasei: investment, 201911– recommended cash offer DKK 8.9b ($1.3b) by Asahi Kasei Pharma Denmark A/S |
2019-11-25 |
| Ventech–SEVERAL: investment, 201803 first closing €140m of Ventech Capital V fund with €200m target size |
2018-03-07 |
| Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc |
2019-03-21 |
| Visiopharm–ATP (DK): investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK45m from new + lead investor ATP |
2018-08-24 |
| Visiopharm–CL David Foundation: investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK15m from new investor CL David Foundation |
2018-08-24 |
| Visiopharm–Denmark (govt): investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK20m from new investor Danish Growth Fund |
2018-08-24 |
| Visiopharm–Northcap Venture Partners: investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK15m from existing investor Northcap |
2018-08-24 |
| Visiopharm–SEVERAL: investment, 201808 financing round DKK100m (€13.3m) led by new investor ATP |
2018-08-24 |
| Vivet Therapeutics–Columbus Venture Partners: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor CVP |
2017-05-04 |
| Vivet Therapeutics–Eurazeo: investment, 201705 financing round Series A totalling €37.5m incl co-investor Kurma Partners |
2017-05-04 |
| Vivet Therapeutics–Novartis: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor Novartis Venture Fund |
2017-05-04 |
| Vivet Therapeutics–Odlander Fredrikson: investment, 201705 financing round Series A totalling €37.5m incl co-investor HealthCap |
2017-05-04 |
| Vivet Therapeutics–Roche: investment, 201705 financing round Series A totalling €37.5m incl co-investor Roche Venture Fund |
2017-05-04 |
| Vivet Therapeutics–SEVERAL: investment, 201705 financing round Series A €37.5m led by Novartis Venture Fund + Columbus Venture Partners |
2017-05-04 |
| Vivet Therapeutics–Ysios Capital: investment, 201705 financing round Series A totalling €37.5m incl co-investor Ysios Capital |
2017-05-04 |
| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| Wilson Therapeutics–Alexion: investment, 201804–201805 cash tender offer SEK7.1b ($855m) with SEK232/share by Alexion |
2018-04-11 |
| Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group |
2019-01-22 |
| Wren Therapeutics–LifeForce Capital: investment, 201901 financing round Series A totalling £18m including co-investor LifeForce Capital |
2019-01-22 |
| Wren Therapeutics–SEVERAL: investment, 201901 financing round Series A £18m from Baupost Group + LifeForce Capital + high net worth individuals |
2019-01-22 |
| Xbrane–SEVERAL: investment, 2016 IPO SEK100m at Nasdaq First North |
2016-01-01 |
| XNK Therapeutics–Flerie Invest: investment, 202203–202204 private placement totalling SEK132m incl SEK100m from new + lead investor Flerie Invest |
2022-03-29 |
| XNK Therapeutics–SEVERAL: investment, 202203–202204 private placement SEK132m led by Flerie Invest AB with SEK100m |
2022-03-29 |
| Yahong Meditech–Photocure: Cevira®, 201907– license ww developm + commercialisation to Asieris up to $250m milestones + royalties |
2019-07-01 |
| Yingsheng Biotechnology–Biotage: clinical mass spectrometry, 201906– collab strategic + OEM sale in China by Shandong Yingsheng Biotechnology |
2019-06-04 |
| Zealand Pharma–SEVERAL: investment, 201707–201708 US IPO of ADSs DKK566.4m at DKK112.58/share at Nasdaq Global Select Market |
2017-07-06 |
| Zelluna–Glycostem Therapeutics: cell therapy contract manufacturing, 201911– collab developm + supply of TCR-guided NK-cell therapies |
2019-11-19 |
| Zelluna–Image Box: public relations, 201810 supply service existent by Image Box PR |
2018-10-24 |
| Zelluna–SEVERAL: grant, 202006 public grants + equity financing tog totalling €7.5m |
2020-06-11 |
| Zelluna–SEVERAL: investment, 202006 equity financing tog with public grants totalling €7.5m |
2020-06-11 |
| Ziylo–Novo Group: investment, 201808 acquisition 100% for up to $800m in upfront + milestone payments by Novo Nordisk |
2018-08-17 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
